Tag: CC20

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

azithromycin stemlyns covid-19

JC: Azithromycin in patients hospitalised with COVID-19

As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were first hearing about a respiratory

The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s

A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have been shown to strongly correlate

Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s

A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring systems over many years (for

Tocilizumaybe? Immune modulation in COVID-19 @StEmlyns

I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is COVID19. This follows a press

COVID-19 testing

Understanding COVID-19 testing with Rick Body. St Emlyn’s

This week Simon and Rick got together to talk through the latest technologies, uses and performance of COVID-19 testing. We think it’s a really useful listen to understand the strengths and weaknesses of the various

JC: Convalescent plasma in COVID 19 patients.

This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes plasma, together with antibodies from

JC: Blood Products in Trauma – What’s the Best (I)TACTIC?

Bleeding trauma patients present a couple of challenges to us in the Emergency Department. Increasingly, our aging population continues to engage in energetic daily pursuits while increasing numbers are prescribed newer direct oral anticoagulant treatments

VTE and COVID-19: Would you like to know more?

That’s a leading question. Of course you would.  Who wouldn’t want to know more about a disease that has killed >1 million people to date, worldwide. Who wouldn’t want to know more about the thromboembolic risk associated

JC: Hydroxychloroquine in the the treatment of hospitalised COVID19 patients.

We previously covered the RECOVERY trial press release on the use of HCQ for hospitalised patients with COVID19. This is a UK based platform trial (more on this later) looking at patients admitted to hospital

Translate »